Metabolomic study in head and neck cancer patients receiving concurrent chemoradiotherapy (CCRT) and Hydrogen gas inhalation: Pilot study

Status

Unknown

Phases

Phase 2

Study type

Interventional

Source

TCTR

Registry ID

TCTR20240515006

Enrollment

Registered

2024-05-15

Start date

2024-03-13

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The serum metabolome in 2 groups of locally advanced head and neck cancer patients who will be treated with CCRT plus H2 gas inhalation versus CCRT alone. Metabolome, Metabolomic, Hydrogen gas, Hydrogen gas Inhalation, Concurrent chemoradiotherapy, Locally advanced head and neck cancer

Interventions

CCRT with daily H2 gas inhalation.,CCRT alone

Experimental Device,No Intervention Other

H2 gas inhalation ,Control

Eligibility

Sex/Gender

All

Age

20 Years to 70 Years

Inclusion criteria

Inclusion criteria: Loco-regional advanced stage HNC. Histologically-proven diagnosis of HNC. Eastern Cooperative Oncology Group (ECOG) performance status 0-2. Able to provide informed consent.

Exclusion criteria

Exclusion criteria: Distant metastasis or locoregional recurrence disease. Contraindications to RT or chemotherapy or Hydrogen gas inhalation. Previous head and neck irradiation. Patients with tracheostomy tube.

Design outcomes

Primary

Measure	Time frame
Metabolome Before and end of CCRT. The proton NMR spectrum will be recorded and acquired using a Bruker AVANCE 500 MHz instrument.	—

Secondary

Measure	Time frame
Safety of hydrogen gas inhalation During CCRT Descriptive	—

Countries

Thailand

Contacts

Public ContactImjai Chitapanarux

Faculty of Medicine, Chiang Mai University

imjai@hotmail.com053935456

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026